Dr. Reddy's Laboratories Ltd. has announced the launch of Elobixibat, a first-in-class drug for the treatment of chronic constipation, in India. The drug will be marketed under the brand name BixiBat.
The launch follows approval from the Central Drugs Standard Control Organisation (CDSCO), which was granted after a successful Phase-3 clinical trial. Dr. Reddy's is the first company to receive approval for and launch Elobixibat in India.
Mechanism of Action
According to the company, Elobixibat works by inhibiting the reabsorption of bile acids from the ileum. This increases the concentration of bile acids in the colonic lumen, leading to increased bowel movements through the stimulation of colonic motility and fluid secretion, irrespective of transit speed.
Addressing Unmet Needs
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr. Reddy’s, stated that the launch of BixiBat is part of the company's ongoing efforts to bring novel molecules to patients in India. He highlighted Dr. Reddy’s expertise in the gastrointestinal segment, noting that BixiBat will address unmet patient needs and improve the quality of life for those suffering from chronic constipation. Clinical studies have shown promising outcomes, positioning BixiBat as a breakthrough drug in managing chronic constipation and enhancing the current standard of care in India.
Market Context
Studies in Asia indicate that nearly 40% of patients with chronic constipation are dissatisfied with current treatment options. Approximately 12% of the Indian population experiences symptoms of constipation, which significantly impacts their quality of life.
